Cevec is joining forces with US-based Paragon. The objective is to make Cevec’s scalable CAP expression technology the industry standard for glycoproteins and viral vectors in gene therapies.
Based in Cologne (Germany), Cevec tackles with its human cell-based expression systems (CAP-GT and CAP-Go) two big challenges in Biotech manufacturing – industrial scale production of viral vectors and complex glycoproteins.
CAP-GT is a platform to produce viral vectors, such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). These viral vectors are used to carry genetic information to the target cells in the patient’s body in gene therapy.
Cevec’s production of viral vectors has two key advantages – scalability and safety. Still, one of the biggest bottlenecks in gene therapy is the ability to produce reliable and safe vectors on an industrial scale to allow the commercial production of gene therapy products.
CAP–GT addresses both: it provides a fully scalable production process based on human suspension cell lines that proved to produce non-replicable adenoviruses.